Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd Expands CNS Specialty Business with Acquisition of NuPathe


Tuesday, 21 Jan 2014 07:00am EST 

Teva Pharmaceutical Industries Ltd:Says that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc for $3.65 per share in cash, or approximately $144 million.Says in addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe`s migraine treatment, ZECUITY, are achieved over time.Says the transaction is expected to be completed in Feb. 2014.